Therefore, a therapeutic approach solely based on a single B-cell factor may not be appropriate in this scenario, as demonstrated by the modest, albeit significant, the clinical effect of anti-BLyS therapies in RA [reviewed in (16)], in contrast to SLE, where BLyS plays a prominent pathogenic role. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.